NANOBIOTIX to Participate in Jefferies London Healthcare Conference

NANOBIOTIX, a biotechnology company focusing on innovative nanotherapeutic approaches for treating cancer and significant diseases, has announced its participation in the Jefferies London Healthcare Conference. Scheduled for November 17, 2025, at 3 PM GMT (10 AM ET), this event will take place in London, UK. CEO Laurent Levy and CFO Bart van Rhijn will engage in a fireside chat that aims to share insights into the company's latest advancements and strategic vision.

The event will be accessible through a live webcast on the Investors section of NANOBIOTIX's website, with a replay available later for those unable to attend. Founded in 2003 and headquartered in Paris, NANOBIOTIX operates in both Europe and the United States, being listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market since December 2020.

NANOBIOTIX specializes in groundbreaking, physics-based therapies designed to improve treatment outcomes and expand possibilities for patients confronting severe health challenges. The company has a robust intellectual property portfolio, featuring over 25 patent families related to three primary nanotechnology platforms, reflecting their commitment to innovation in oncology, bioavailability and biodistribution, and central nervous system disorders.

With a driven team focused on making a tangible difference in human health, NANOBIOTIX is poised to advance its mission of redefining treatment paradigms for patients. For further details, interested parties can visit the company's website at www.nanobiotix.com or engage with them on social media platforms like LinkedIn and Twitter. The conference participation underscores the company's dedication to driving healthcare innovation and engaging with the broader investment community.

As Nanobiotix (Euronext: NANO; NASDAQ: NBTX) prepares to participate in the Jefferies London Healthcare Conference on November 17, 2025, investors should closely monitor the insights shared during the fireside chat. This event presents a pivotal opportunity for strategic communication from CEO Laurent Levy and CFO Bart van Rhijn, especially given the company's late-stage clinical advancements in nanotherapeutic oncology treatments.

Nanobiotix’s innovative approach to cancer therapy through nanotechnology positions it favorably within a competitive biotechnology landscape. With patents covering three distinct platforms—oncology, bioavailability, and central nervous system disorders—the company boasts a diverse portfolio that may attract interest from a variety of stakeholders. This diversification is particularly relevant as cancer treatment continues to be a top priority for both healthcare systems and investors.

As the company grows, it is essential to evaluate its recent clinical trial results and any new data shared at the conference. Updates on regulatory pathways and partnerships will also be significant indicators of future performance. Given that the company is already publicly traded on Euronext and NASDAQ, investors can take advantage of market fluctuations following the conference's insights.

Strategically, consider using a mixed investment approach by allocating a portion of your portfolio to Nanobiotix while monitoring market reactions and upcoming trial results. Engaging with the conference through the live webcast or recorded session can provide valuable data insights and foster informed investment decisions.

As with any investment in biotech firms, remain cautious of volatility and conduct further research into the company’s financial health and market conditions. Nanobiotix’s innovative trajectory could potentially yield impactful returns, making it a noteworthy asset for investors looking to tap into the transformative landscape of cancer treatment.